Meningococcal Infections

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

5100%

+ 10 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

SandozAustria - Kundl

5 programs

MenACWY CRMPhase 3

MenACWY-CRMPhase 3

MenACWY-CRM + MMRVPhase 3

NZ MenB OMV vaccinePhase 2Vaccine

rMenB+OMV NZPhase 2

EyeGeneKorea - Uiwang

1 program

EG-MCV4Phase 2/31 trial

Active Trials

NCT07204457Recruiting1,123Est. Jun 2027

Public Health VaccinesMA - Cambridge

1 program

NZ MenB OMV vaccinePhase 2Vaccine

NovartisBASEL, Switzerland

4 programs

NZ MenB OMV vaccinePHASE_2Vaccine1 trial

MenACWY CRMPHASE_31 trial

MenACWY-CRMPHASE_31 trial

MenACWY-CRM + MMRVPHASE_31 trial

Active Trials

NCT00774384Completed9Est. Nov 2011

NCT00450437Completed3,539Est. Jan 2008

NCT00616421Completed2,907Est. Oct 2009

+1 more trials

GSKLONDON, United Kingdom

1 program

4CMenbN/A1 trial

Active Trials

NCT02712177Completed4,535Est. Apr 2019

ViiV HealthcareNC - Durham

1 program

4CMenbN/A

Walvax BiotechnologyChina - Kunming

1 program

Meningococcal Group ACYW135 Conjugate VaccinePHASE_1Vaccine1 trial

Active Trials

NCT04236960Completed100Est. Nov 2019

SanofiPARIS, France

1 program

MenACYW conjugate vaccinePHASE_3Vaccine5 trials

Active Trials

NCT06647407Active Not Recruiting750Est. May 2027

NCT06284915Completed840Est. Nov 2025

NCT06128733Completed1,215Est. Aug 2025

+2 more trials

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

SanofiMenACYW conjugate vaccine

NovartisMenACWY-CRM

NovartisMenACWY-CRM + MMRV

NovartisMenACWY CRM

EyeGeneEG-MCV4

NovartisNZ MenB OMV vaccine

SanofiMenACYW conjugate vaccine

Walvax BiotechnologyMeningococcal Group ACYW135 Conjugate Vaccine

GSK4CMenb

Clinical Trials (14)

Total enrollment: 22,209 patients across 14 trials

NCT06284915 SanofiMenACYW conjugate vaccine

Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers

Start: Mar 2024Est. completion: Nov 2025840 patients

Phase 3Completed

NCT03547271 SanofiMenACYW conjugate vaccine

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Start: Dec 2018Est. completion: May 20231,660 patients

Phase 3Completed

NCT03537508 SanofiMenACYW conjugate vaccine

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Start: Apr 2018Est. completion: Sep 20232,627 patients

Phase 3Completed

NCT03476135 SanofiMenACYW conjugate vaccine

Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

Start: Feb 2018Est. completion: Sep 201891 patients

Phase 3Completed

NCT03205371 SanofiMenACYW conjugate vaccine

Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers

Start: Nov 2016Est. completion: Jul 20181,183 patients

Phase 3Completed

NCT00616421 NovartisMenACWY-CRM

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

Start: Mar 2008Est. completion: Oct 20092,907 patients

Phase 3Completed

NCT00626327 NovartisMenACWY-CRM + MMRV

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

Start: Feb 2008Est. completion: Oct 20101,630 patients

Phase 3Completed

NCT00450437 NovartisMenACWY CRM

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

Start: Mar 2007Est. completion: Jan 20083,539 patients

Phase 3Completed

NCT07204457 EyeGeneEG-MCV4

Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old

Start: Oct 2025Est. completion: Jun 20271,123 patients

Phase 2/3Recruiting

NCT00774384 NovartisNZ MenB OMV vaccine

Regulation of Mucosal Immune Response to Systemic MenB Vaccine

Start: Sep 2009Est. completion: Nov 20119 patients

Phase 2Completed

NCT06647407 SanofiMenACYW conjugate vaccine

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

Start: Nov 2024Est. completion: May 2027750 patients

Phase 1/2Active Not Recruiting

NCT06128733 SanofiMenACYW conjugate vaccine

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Start: Oct 2023Est. completion: Aug 20251,215 patients

Phase 1/2Completed

NCT04236960 Walvax BiotechnologyMeningococcal Group ACYW135 Conjugate Vaccine

Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.

Start: Jul 2018Est. completion: Nov 2019100 patients

Phase 1Completed

NCT02712177 GSK4CMenb

Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization

Start: Aug 2008Est. completion: Apr 20194,535 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 22,209 patients

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.